Sun, Dec 21, 2014, 12:32 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • rakanobo rakanobo Dec 11, 2013 9:48 AM Flag

    NBS is a Must Buy over the next 12 months

    As of November, NBS was 10 patients shy of reaching full enrollment for its Phase 2 trial. Let me say it again, 10 PATIENTS SHY! The announcement of complete enrollment could come any day, or at any second!

    Once that happens, NBS will soar at least 10% because it means we are 6-9 months from final data. AMR-001 already has good data, and Baxter's data has been remarkable with its CD34+ product.

    There will be a lot of anticipation and NBS will get a pre-data run higher. The stock could easily be $11 by the time data is announced, and if positive, NBS will be a $25 stock.

    If for some reason data is bad, unlikely, NBS will be a $4 stock. Therefore, assess the upside/downside and you'll see that there's not much to lose, but a lot to gain.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.34+0.090(+2.77%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST